Catalyst
Slingshot members are tracking this event:
ENLIGHTEN pivotal program initiated for ALKS 3831 in treating Schizophrenia and EVOLVE-1 for ALKS 8700 in treatment of Multiple Sclerosis
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALKS |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 16, 2015
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Alks 3831, Schizophrenia, Alks 8700, Multiple Sclerosis, Atypical Antipsychotic Drug Candidate, Oral Monomethyl Fumarate, Mmf
